Kimberly Gentile
Net Worth

Last updated:

What is Kimberly Gentile net worth?

The estimated net worth of Ms. Kimberly Gentile is at least $9,454,160 as of 3 Oct 2022. She owns shares worth $338,890 as insider, has earned $3,875,350 from insider trading and has received compensation worth at least $5,239,920 in Biohaven Pharmaceutical Holding Company Ltd..

What is the salary of Kimberly Gentile?

Ms. Kimberly Gentile salary is $654,990 per year as Senior Vice President of Clinical Operations in Biohaven Pharmaceutical Holding Company Ltd..

How old is Kimberly Gentile?

Ms. Kimberly Gentile is 59 years old, born in 1966.

What stocks does Kimberly Gentile currently own?

As insider, Ms. Kimberly Gentile owns shares in one company:

Company Title Shares Price per share Total value
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Senior Vice President of Clinical Operations 21,878 $15.49 $338,890

What does Biohaven Pharmaceutical Holding Company Ltd. do?

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

BHVN logo
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
$15.49

Kimberly Gentile insider trading

Biohaven Pharmaceutical Holding Company Ltd.

Ms. Kimberly Gentile has made 13 insider trades between 2017-2022, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 37,500 units of BHVN stock on 3 Oct 2022. As of 3 Oct 2022 she still owns at least 21,878 units of BHVN stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Shares 12,612 $6.37 $80,338
Option
Stock Option (Right to Buy) 37,500 $0.54 $20,250
Option
Common Shares 12,500 $0.54 $6,750
Option
Common Shares 4,500 $1.86 $8,370
Option
Common Shares 20,716 $1.03 $21,337
Option
Common Shares 387 $6.37 $2,465
Option
Common Shares 295 $1.03 $304
Option
Common Shares 1,542 $1.61 $2,483
Option
Common Shares 30,958 $1.61 $49,842
Option
Common Shares 3,000 $2.52 $7,560
Option
Common Shares 14,000 $2.84 $39,760
Option
Common Shares 13,801 $4.13 $56,998
Option
Common Shares 1,199 $4.13 $4,952
Option
Restricted Share Unit Award 3,750 N/A N/A
Option
Common Shares 3,750 N/A N/A
Option
Restricted Share Unit Award 3,750 N/A N/A
Option
Common Shares 3,750 N/A N/A
Option
Common Shares 3,750 N/A N/A
Option
Restricted Share Unit Award 3,750 N/A N/A
Option
Restricted Share Unit Award 3,750 N/A N/A
Option
Common Shares 3,750 N/A N/A
Sale
Common Shares 23,500 $76.49 $1,797,421
Option
Common Shares 23,500 $9.29 $218,315
Sale
Employee Stock Option (Right to Buy) 23,500 $9.29 $218,315
Sale
Common Shares 24,000 $5.6 $134,400
Option
Common Shares 24,400 $5.6 $136,640
Option
Employee Stock Option (Right to Buy) 24,000 $5.6 $134,400
Sale
Employee Stock Option (Right to Buy) 400 $5.6 $2,240
Option
Common Shares 600 $5.6 $3,360
Sale
Common Shares 600 $5.6 $3,360
Option
Employee Stock Option (Right to Buy) 600 $5.6 $3,360
Option
Employee Stock Option (Right to Buy) 1,590 $29.17 $46,372
Option
Common Shares 1,590 $29.17 $46,372
Option
Restricted Share Unit Award 3,750 N/A N/A
Option
Common Shares 3,750 N/A N/A
Option
Common Shares 21,065 $53.04 $1,117,203
Option
Employee Stock Option (Right to Buy) 21,065 $53.04 $1,117,203
Sale
Common Shares 21,065 $53.04 $1,117,203
Option
Employee Stock Option (Right to Buy) 3,935 $0.61 $2,400
Sale
Common Shares 3,935 $0.61 $2,400
Option
Common Shares 3,935 $0.61 $2,400
Option
Common Shares 12,500 $0.61 $7,625
Sale
Common Shares 12,500 $0.61 $7,625
Option
Employee Stock Option (Right to Buy) 12,500 $0.61 $7,625
Sale
Common Shares 5,000 $32.93 $164,650
Option
Employee Stock Option (Right to Buy) 5,000 $0.61 $3,050
Option
Common Shares 5,000 $0.61 $3,050
Option
Common Shares 5,000 $0.61 $3,050
Option
Employee Stock Option (Right to Buy) 5,000 $0.61 $3,050
Sale
Common Shares 5,000 $33.3 $166,485
Option
Employee Stock Option (Right to Buy) 5,000 $0.61 $3,050
Option
Common Shares 5,000 $0.61 $3,050
Sale
Common Shares 5,000 $0.61 $3,050
Option
Employee Stock Option (Right to Buy) 5,000 $0.61 $3,050
Sale
Common Shares 5,000 $22.25 $111,250
Option
Common Shares 5,000 $0.61 $3,050
Sale
Common Shares 5,000 $29.39 $146,950
Option
Employee Stock Option (Right to Buy) 5,000 $0.61 $3,050
Option
Common Shares 5,000 $0.61 $3,050

Biohaven Pharmaceutical Holding Company Ltd. key executives

Biohaven Pharmaceutical Holding Company Ltd. executives and other stock owners filed with the SEC:

  • Dr. Elyse Stock M.D. (67) Chief Medical Officer
  • Dr. Vladimir Coric M.D. (54) Chairman, Chief Executive Officer & Pres
  • Mr. William Jones M.B.A. (61) Chief Commercial Officer of Migraine & Common Diseases
  • Ms. Kimberly Gentile (59) Senior Vice President of Clinical Operations